Drug Profile
Ferric citrate - PUMC Pharmaceutical
Alternative Names: FC 818Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator PUMC Pharmaceutical Company
- Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Hyperphosphataemia
Most Recent Events
- 06 Apr 2021 Phase-III development for Hyperphosphataemia is ongoing in China (PO, Tablet) (PUMC Pharmaceutical pipeline, April 2021)